| Q36901903 | Augmented central pain processing in vulvodynia |
| Q26851581 | Central changes associated with chronic pelvic pain and endometriosis |
| Q34144741 | Central sensitization: Implications for the diagnosis and treatment of pain |
| Q33583445 | Etiology, diagnosis, and clinical management of vulvodynia |
| Q34100395 | Impact of educational seminars on women with provoked vestibulodynia |
| Q35640436 | Intradermal capsaicin as a neuropathic pain model in patients with unilateral sciatica |
| Q38529985 | Is the 2003 ISSVD terminology and classification of vulvodynia up-to-date? A neurobiological perspective |
| Q35607937 | Natural history of comorbid orofacial pain among women with vestibulodynia |
| Q36990414 | Overlap between orofacial pain and vulvar vestibulitis syndrome |
| Q34004189 | Potency and Stability of Intradermal Capsaicin: Implications for Use as a Human Model of Pain in Multicenter Clinical Trials |
| Q38197683 | Provoked vestibulodynia: inflammatory, neuropathic or dysfunctional pain? A neurobiological perspective. |
| Q35257099 | Psychological factors in chronic pelvic pain in women: relevance and application of the fear-avoidance model of pain |
| Q37187807 | Rationale and design of a multicenter randomized clinical trial of extended release gabapentin in provoked vestibulodynia and biological correlates of response |
| Q28076559 | Recent advances in understanding provoked vestibulodynia |
| Q92567453 | Sexual pain and IC/BPS in women |
| Q35229804 | Site-specific mesenchymal control of inflammatory pain to yeast challenge in vulvodynia-afflicted and pain-free women |
| Q28484151 | The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica |
| Q42784439 | Toward a better understanding of the relationship between vulvodynia and chronic stressors |
| Q34024592 | Vulvodynia and chronic pelvic and perineal pain |
| Q38214429 | Vulvodynia: Current state of the biological science |